Civamide Nasal Spray for the Treatment of Dry Eye
Civamide 鼻喷雾剂治疗干眼症
基本信息
- 批准号:10384841
- 负责人:
- 金额:$ 16.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2022-08-11
- 项目状态:已结题
- 来源:
- 关键词:AdultAdverse effectsAdverse eventAffectAgreementBlurred visionChicagoClinical ResearchCommunitiesControlled StudyCorneaDevelopmentDiseaseDoseDouble-Blind MethodDrug InteractionsDrug KineticsDry Eye SyndromesEnrollmentEpisodic Cluster HeadachesEsthesiaEyeFatigueFeelingFilmForeign BodiesFormulationFundingGlandGoalsGrantHeadache DisordersLacrimationLeadLicensingMeasurableMeasuresMediatingMedicalMigraineMucous MembraneNerveNerve EndingsNeurotransmittersNoseOphthalmologistOutcomePainParticipantPatient CarePatientsPersonsPharmaceutical PreparationsPhasePhysiologyPruritusRandomizedRednessResearchSafetySerious Adverse EventSeverity of illnessSigns and SymptomsSmall Business Innovation Research GrantStructure of mucous membrane of noseSurfaceSymptomsTestingTherapeuticTherapeutic EffectTissuesTrigeminal nerve structureVisionabsorptionassociated symptomclinical developmentcommercializationeffective therapyexperienceeye drynessinclusion criteriaindexinginnovationirritationneurotransmitter transportnovelnovel strategiesnovel therapeuticsopen labelphase 2 studyphase 3 studyprimary outcomereceptorresearch and developmentscreeningside effecttreatment durationtreatment research
项目摘要
7. Project Summary/Abstract
The project is a Phase II clinical study of Civamide Nasal Spray for the treatment of Dry Eye Disease, an
irritating and potentially severely disabling ocular disease. If this study is successful in the treatment of Dry Eye
Disease, further clinical development will proceed, i.e., Phase 3 studies to support the filing of a New Drug
Application. Currently, all approved medications for treating Dry Eye Disease are directly instilled into the eye
with the possibility of ocular side effects. Civamide Nasal Spray is unique in that it exerts its therapeutic effect
locally in the nasal mucosa without systemic absorption being detected, as shown in a pharmacokinetic study.1
The availability of a safe and effective medication for Dry Eye Disease for these patients, i.e., Civamide Nasal
Spray, will thus fill an unmet medical need.
Civamide, a TRPV-1 receptor modulator,2,3 is a medication with a mechanism of action that affects nerves by
modulating the synthesis, release, and transport of neurotransmitters. Dry Eye Disease is a disease of the
surface of the eye, tear film, and related ocular tissues, including mucosal glands, which in part, are innervated
by the trigeminal nerve.4,5,6 The trigeminal nerve also has superficial nerve endings in the nasal mucosa, which
are the targets of Civamide Nasal Spray. By affecting these nerve endings, neurotransmitter physiology is
affected throughout the entire nerve. Increased lacrimation as a result of this novel mechanism of action has
been observed when Civamide Nasal Spray is applied to the nasal mucosa in both normal subjects and
subjects with headache disorders mediated by the trigeminal nerve, e.g., migraine headache7 and cluster
headache8.
This proposed study is a 12 week, double-blind, vehicle-controlled study of adult subjects that have moderate
to severe Dry Eye Disease for at least 6 months, and a Schirmer’s Test of ≤ 8 per 5 minutes in at least one eye
at screening and baseline. The study is composed of a non-treatment Screening Period during which subjects
will be required to meet study inclusion criteria, followed by a 12-week Double-Blind Treatment Period.
Subjects will be randomized 1:1, approximately 20 subjects per group. The primary outcome variable will be
the change in the Schirmer’s Test from Baseline to Day 84 of the Treatment Period. Adverse events will be
recorded during the study.
7. 项目总结/摘要
该项目是Civamide鼻喷雾剂治疗干眼症的II期临床研究。
刺激性且可能严重致残的眼部疾病。如果这项研究成功治疗干眼症
疾病,将进行进一步的临床开发,即支持新药申请的三期研究
应用。目前,所有批准治疗干眼病的药物都是直接滴入眼睛
可能会产生眼部副作用。 Civamide鼻喷雾剂的独特之处在于它发挥了治疗作用
如药代动力学研究所示,局部存在于鼻粘膜中,未检测到全身吸收。1
为这些患者提供安全有效的干眼病药物,即 Civamide Nasal
喷雾剂将因此填补未满足的医疗需求。
Civamide 是一种 TRPV-1 受体调节剂,2,3 是一种具有通过以下方式影响神经的作用机制的药物:
调节神经递质的合成、释放和运输。干眼症是一种疾病
眼睛表面、泪膜和相关眼组织,包括部分受神经支配的粘膜腺
由三叉神经支配。4,5,6 三叉神经在鼻粘膜中也有浅表神经末梢,
是 Civamide 鼻喷雾剂的目标。通过影响这些神经末梢,神经递质生理学
影响整个神经。这种新颖的作用机制导致流泪增加
当将 Civamide 鼻喷雾剂施用于正常受试者和受试者的鼻粘膜时,观察到
患有由三叉神经介导的头痛疾病的受试者,例如偏头痛7和丛集性头痛
头痛 8.
这项拟议的研究是一项为期 12 周的双盲、媒介对照研究,对象为患有中度糖尿病的成人受试者。
患有严重干眼病至少 6 个月,并且至少一只眼睛的 Schirmer 测试每 5 分钟 ≤ 8
在筛选和基线时。该研究由一个非治疗筛选期组成,在此期间受试者
需要满足研究纳入标准,然后是 12 周的双盲治疗期。
受试者将以 1:1 的比例随机分配,每组大约 20 名受试者。主要结果变量将是
Schirmer 测试从基线到治疗期第 84 天的变化。不良事件将会
研究期间记录。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Scott Phillips其他文献
Scott Phillips的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Scott Phillips', 18)}}的其他基金
Naloxone Lotion for the Treatment of Pruritus in Mycosis Fungoides
纳洛酮洗剂治疗蕈样肉芽肿瘙痒症
- 批准号:
9346005 - 财政年份:2016
- 资助金额:
$ 16.03万 - 项目类别:
Naloxone Lotion for the Treatment of Pruritus in Mycosis Fungoides
纳洛酮洗剂治疗蕈样肉芽肿瘙痒症
- 批准号:
9999503 - 财政年份:2016
- 资助金额:
$ 16.03万 - 项目类别:
Naloxone Lotion for the Treatment of Pruritus in Mycosis Fungoides
纳洛酮洗剂治疗蕈样肉芽肿瘙痒症
- 批准号:
9165686 - 财政年份:2016
- 资助金额:
$ 16.03万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 16.03万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 16.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 16.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 16.03万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 16.03万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 16.03万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 16.03万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 16.03万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 16.03万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 16.03万 - 项目类别:
Discovery Grants Program - Individual